A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy
暂无分享,去创建一个
David A Morrow | E. Antman | R. Giugliano | E. Braunwald | D. Morrow | A. Charlesworth | Richard Cairns | S. Murphy | C. McCabe | J. Lemos | Elliott M Antman | Robert P Giugliano | Sabina A Murphy | Eugene Braunwald | James A de Lemos | Andrew Charlesworth | Richard Cairns | Carolyn H McCabe | C. Mccabe
[1] W D Weaver,et al. 31st Bethesda Conference. Emergency Cardiac Care. Task force 2: Acute coronary syndromes: Section 2A--Prehospital issues. , 2000, Journal of the American College of Cardiology.
[2] D. Jacobs,et al. PREDICT: A simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey. , 1999, Circulation.
[3] W. O’Neill,et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. , 1991, Annals of internal medicine.
[4] H. Krumholz,et al. Comparing AMI mortality among hospitals in patients 65 years of age and older: evaluating methods of risk adjustment. , 1999, Circulation.
[5] C. Cannon,et al. ER TIMI-19: testing the reality of prehospital thrombolysis. , 2000, The Journal of emergency medicine.
[6] J. Rouleau,et al. Myocardial infarction patients in the 1990s--their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. , 1996, Journal of the American College of Cardiology.
[7] InTIME-II Investigators,et al. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. , 2000, European heart journal.
[8] E. Antman. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.
[9] W. Weaver,et al. The prehospital electrocardiogram in acute myocardial infarction: is its full potential being realized? National Registry of Myocardial Infarction 2 Investigators. , 1997, Journal of the American College of Cardiology.
[10] E. Antman. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. , 1994, Circulation.
[11] C. Naylor,et al. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. , 1996, Journal of the American College of Cardiology.
[12] E. Braunwald,et al. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. , 1990, Journal of the American College of Cardiology.
[13] J. Hanley,et al. The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.
[14] B. McNeil,et al. Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients. Results from the Cooperative Cardiovascular Project. , 1996, JAMA.
[15] E. Antman,et al. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy , 2000, Circulation.
[16] J Col,et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.